Emergent BioSolutions will participate in May investor conferences
The conferences include the Mizuho Securities USA Second Annual Healthcare Corporate Access Day, which will take place on May 6 in New York City; the Bank of America Merrill Lynch 2014 Health Care Conference on May 13 in Las Vegas; and the UBS Global Healthcare Conference on May 19 in New York City.
During the Mizuho Securities USA conference, Emergent will participate in one-on-one meetings, as the format of the conference does not include formal presentations.
For the UBS and Bank of America Merrill Lynch conferences, Emergent will webcast its formal presentations. The presentations will encompass a corporate overview and may include a discussion of Emergent's financial results and financial guidance for the current year and latest quarter. The company will make the webcasts available live and by replay on its website.
Emergent BioSolutions is a specialty pharmaceutical company that develops specialized products to healthcare providers and governments to meet emerging health threats and medical needs. Emergent's biodefense products include its anthax vaccine BioThrax; VIGIV, also known as vaccinia immune globulin intravenous for humans; and BAT, an equine botulism antitoxin heptavalent.